Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma
Protocol ID
J10-MC-JZHD
Disease (Sub Disease)
Solid tumours
Diagnosis Stage
Relapsed/ refractory
Sponsor
Eli Lilly and Company
Collaborators
New Approaches to Neuroblastoma Therapy Consortium (NANT)
Innovative Therapies for Children with Cancer in Europe (ITCC)
Innovative Therapies for Children with Cancer in Europe (ITCC)
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 1
Age Eligibility
2 years to 21 years
International registry ID's
NCT04106219
| Study Title | A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma |
|---|---|
| Protocol ID | J10-MC-JZHD |
| Disease (Sub Disease) | Solid tumours |
| Diagnosis Stage | Relapsed/ refractory |
| Sponsor | Eli Lilly and Company |
| Collaborators | New Approaches to Neuroblastoma Therapy Consortium (NANT)/ Innovative Therapies for Children with Cancer in Europe (ITCC) |
| Links | https://clinicaltrials.gov/ct2/show/NCT04106219 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 11/06/2020 |
| Study Type | Treatment |
| Phase | Phase 1 |
| Age Eligibility | 2 years to 21 years |
| International registry ID's | NCT04106219 |